🏛️ Verified NIH Record • Updated 2026-07-02
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (NCT02489318)
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Aragon Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Homewood, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (220 Sites)
Showing the first 25 of 220 sites.
- Clinical Research Facility — Homewood, Alabama
- Clinical Research Facility — Tucson, Arizona
- Clinical Research Facility — San Bernardino, California
- Clinical Research Facility — San Diego, California
- Clinical Research Facility — Denver, Colorado
- Clinical Research Facility — Norwalk, Connecticut
- Clinical Research Facility — Fort Myers, Florida
- Clinical Research Facility — Chicago, Illinois
- Clinical Research Facility — Fort Wayne, Indiana
- Clinical Research Facility — Jeffersonville, Indiana
- Clinical Research Facility — New Orleans, Louisiana
- Clinical Research Facility — Baltimore, Maryland
- Clinical Research Facility — Rockville, Maryland
- Clinical Research Facility — Lansing, Michigan
- Clinical Research Facility — Troy, Michigan
- Clinical Research Facility — Omaha, Nebraska
- Clinical Research Facility — Las Vegas, Nevada
- Clinical Research Facility — Brooklyn, New York
- Clinical Research Facility — Poughkeepsie, New York
- Clinical Research Facility — Syracuse, New York
- Clinical Research Facility — The Bronx, New York
- Clinical Research Facility — Raleigh, North Carolina
- Clinical Research Facility — Salisbury, North Carolina
- Clinical Research Facility — Cleveland, Ohio
- Clinical Research Facility — Middleburg Heights, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.